BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

ARWR upcoming catalysts

Arrowhead Pharmaceuticals: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 0 FDA event(s). Subscribe to ARWR (.ics).

Drugs: Plozasiran, ARO-ALK7

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-02 est.P1/P2Arrowhead Pharmaceuticals ARWRNCT06937203 A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes MellitusObesity; Diabetes Mellitus, Type 2recruiting150

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-06-17P3Arrowhead Pharmaceuticals ARWRNCT06347016 Study of Plozasiran in Adults With Severe HypertriglyceridemiaSevere Hypertriglyceridemiacompleted311
2026-06-12P3Arrowhead Pharmaceuticals ARWRNCT06347003 Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaSevere Hypertriglyceridemiacompleted446
2026-06-01P3Arrowhead Pharmaceuticals ARWRNCT06347133 Phase 3 Study of Plozasiran in Adults With HypertriglyceridemiaHypertriglyceridemiacompleted1456

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.